Meningiomas arise from the meningothelial cells of the dura and has an indolent nature. They account for 30% of all primary intracranial neoplasms. Extracranial meningioma metastasis is extremely rare. A 53-year-old female admitted with amnesia and headache. Subtotal resection was obtained. Tumor histopathology revealed an anaplastic meningioma and the patient received postoperative radiotherapy. Three months later, the patient experienced weakness and bone pain. Cranial MRI excluded local recurrence. Computed tomography revealed liver, bone and subcutaneous metastases. Liver biopsy confirmed the diagnosis of grade 3 meningioma. After receiving chemotherapy, CT showed progression in liver lesions and cranial MRI revealed local recurrence. The patient died 12 months after the primary surgery.

**ABSTRACT** Meningiomas account for 30% of all primary intracranial neoplasms. Extracranial meningioma metastasis is extremely rare. A 53-year-old female admitted with amnesia and headache. Subtotal resection was obtained. Tumor histopathology revealed an anaplastic meningioma and the patient received postoperative radiotherapy. Three months later, the patient experienced weakness and bone pain. Cranial MRI excluded local recurrence. Computed tomography revealed liver, bone and subcutaneous metastases. Liver biopsy confirmed the diagnosis of grade 3 meningioma. After receiving chemotherapy, CT showed progression in liver lesions and cranial MRI revealed local recurrence. The patient died 12 months after the primary surgery.

**Keywords:** Radiotherapy; meningioma; neoplasm metastasis
CASE REPORT

A 53-year-old woman was admitted with amnesia and frontal headache which had lasted for 2 months. A computed tomography (CT) of the head revealed well-defined, irregular lobulated lesion, measuring 6x5 cm in diameter which located in left frontoparietal area. The tumour was hyperdense to normal brain with intratumoural necrosis and an extensive oedema. Further magnetic resonance imaging (MRI) of the brain confirmed the lesion with contrast enhancement. Neurological examination was intact, with no cranial nerve abnormality, consciousness or cognitive deficit.

A left parasagittal craniotomy was performed and subtotal resection was obtained (Figure 1). Hematoxylin and eosin staining showed a pleomorphic, highly proliferative meningeal tumour with an overall high cell density, nuclear atypia as well as areas of necrosis, and numerous mitoses, altogether more than 10BBA in 30 hpf. Immunohistochemical staining with Ki 67 revealed a very high rate of proliferation with a rate of 80% within the tumour tissue, marking 80% most of the meningeal tumour cells displayed immunopositivity for epithelial membrane antigen and S100. These findings were consistent with an anaplastic meningioma with increased mitotic activity (Figures 2, 3, 4).

Postoperatively, the patient had no new neurological deficit and 39x36x22 mm residual tumour was detected in postoperative MRI. She was discharged on the 7th postoperative day with a good performance status. The patient received postoperative intensity-modulated and image-guided radiation therapy (IM/IGRT) with a cumulative dose of 60 Gy.
Three months later, the patient experienced weakness and bone pain localized in right femur and left iliac area. Cranial MRI excluded local recurrence. Computed tomography scan of the chest and upper abdomen revealed multiple liver lesions located in the right side, multiple bone metastases and enlarged lymph nodes without chest lesion (Figure 5). A fluorodeoxyglucose (FDG) positron emission tomography (PET) CT scan showed FDG uptake in predefined CT sites (Figure 6).

Liver biopsy was performed and pathological examination of the resection specimen confirmed the diagnosis of a grade 3 meningioma similar histopathology with primary.

After receiving 5 cycles of cisplatin and etoposide, control abdomen CT showed progression in liver lesions. Meanwhile, she described frontal headache with similar to initial complaint. Magnetic resonance imaging of the brain revealed recurrence lesion at postoperative area that was approximately 55x45 mm in size. The patient refused any further treatment and was received palliative pain management.

The patient died 12 months after the primary intracranial surgery. No autopsy was performed.

DISCUSSION

Meningioma prevalence is 97.5 per 100,000 based on surgical series in the United States and approximately 8000 meningiomas are identified every year. In a recent epidemiologic study, they are found to be the most frequent primary intracranial neoplasm.1

After total resection, locoregional recurrence rates vary from 9% to 32%.9 EMM is rare and has been estimated to occur in less than 0.1% with WHO grade 2 and 3 patients.10 WHO grade II and grade III meningiomas are associated with poor prognosis, higher locoregional recurrence rates and metastases.2,11 In this case report, patient had an initial diagnosis of anaplastic meningioma (WHO grade II).

According to current studies, the lungs (37.2%), are the most common site of metastasis, followed by bone (16.5%), spinal cord (15.2%) and liver (9.2%). In addition, metastases rarely occur in the kidney, bladder, thyroid, or breast.2,3

Pulmonary metastases typically present as single or multiple non-calcified parenchymal nodules without symptoms.12

Metastases are frequently diagnosed after local recurrence. Time to distant metastasis can vary from a few months to several years.3 The mean interval between diagnosis of the primary tumour and EMM is ~6 years, the longest being 24 years.

Associated preidentified risk factors for EMM were, local recurrence, high mitotic activity, nuclear pleomorphism, previous craniotomy, venous sinus invasion, papillary morphology, hypercellularity, cellular heterogeneity.12 Analyses of immunohistochemistry such as the Ki-67 labelling index is useful in defining aggressiveness for recurrence and metastasis.2,7 Recent work has also highlighted several molecular and cytogenetic markers that may predict EMM such as CD90. CD90 a protein associated with aberrant activation
of the self-renewal machinery. CD90 has been previously observed in glioblastomas and may play a role in the formation of tumour vasculature and tumour progression. Scognamiglio and colleagues reported that high expression of CD90 in cases of EMM is a potential marker for metastatic potential. Additionally, Frydrychowicz and colleagues suggested that deletions affecting chromosomes 22 and 1 in primary atypical meningiomas may be associated with metastasis and aggressive progress.

Our patient had most of the identified risk factors for EMM with high mitotic activity, high Ki-67 index and anaplastic histology.

The exact route of metastasis is unknown, haematogenous, lymphatic, and cerebrospinal fluid (CSF) routes. CSF spread may have associated for intraspinal EMM and haematogenous spread for vertebral EMM however it is difficult to confirm.

Complete surgical resection is the treatment of choice for resectable intracranial or intraspinal meningiomas. Adjuvant postoperative radiation therapy has been recommended for the prevention of local recurrence. There are some reports indicating good results obtained with chemotherapy however, traditional chemotherapy has little benefit in malignant meningioma.

In conclusion, distant metastasis of meningioma is extremely rare and it usually seen after local recurrence. When local recurrence occurs or systemic sign and symptoms develop, further screening must be performed to exclude EMM.

Source of Finance
During this study, no financial or spiritual support was received neither from any pharmaceutical company that has a direct connection with the research subject, nor from a company that provides or produces medical instruments and materials which may negatively affect the evaluation process of this study.

Conflict of Interest
No conflicts of interest between the authors and/or family members of the scientific and medical committee members or members of the potential conflicts of interest, counseling, expertise, working conditions, share holding and similar situations in any firm.

Authorship Contributions
Opinion/Concept: İpek Pinar Aral, Mine Şalk| Design: Süheyla Aytacı Arslan| Supervision/Consultancy: Süheyla Aytacı Arslan; Data Collection and/or Processing: İpek Pinar Aral; Analysis and/or Comment: Süheyla Aytacı Arslan; Resource Scanning: İpek Pinar Aral; Combination Writing: Süheyla Aytacı Arslan, İpek Pinar Aral; Critical Investigation: Süheyla Aytacı Arslan, Nuran Sungu; Materials: Nuran Sungu.

REFERENCES